Skip Navigation


Rheumatology Advance Access originally published online on May 19, 2009
Rheumatology 2009 48(7):823-827; doi:10.1093/rheumatology/kep103
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
48/7/823    most recent
kep103v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Seo, P.
Right arrow Articles by Merkel, P. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seo, P.
Right arrow Articles by Merkel, P. A.
Related Collections
Right arrow Vasculitis
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Assessment of damage in vasculitis: expert ratings of damage

Philip Seo1, David Jayne2, Raashid Luqmani3 and Peter A. Merkel4

1Johns Hopkins Vasculitis Center, Johns Hopkins University Division of Rheumatology, Baltimore, MD, USA,2Vasculitis and Lupus Clinic, Addenbrooke's Hospital Department of Renal Medicine, Cambridge,3Botnar Research Centre, University of Oxford, Oxford, UK and 4Boston University Vasculitis Center, Boston University Division of Rheumatology, Boston, MA, USA.

Correspondence to: Philip Seo, 5501 Hopkins Bayview Circle, JHAAC Room 1B.1A, Baltimore, MD 21224, USA. E-mail: seo{at}jhmi.edu


   Abstract

Objectives. Current measures of damage in vasculitis do not account for the possibility that some forms of damage may exert greater impact than others. As part of an international effort to revise how damage is quantified in vasculitis clinical research, an exercise was performed to measure expert ratings of damage items.

Methods. Members of the Vasculitis Clinical Research Consortium and European Vasculitis Study Group were given a list of 129 items of damage related to WG and microscopic polyangiitis (MPA). Participants were asked to rate each item of damage on an integer scale from 0 to 10, where 10 represented the most severe form of damage and 0 indicated ‘no impact’.

Results. A multidisciplinary panel of 50 investigators from North America, Europe and Australia–New Zealand participated. The highest median ratings (8–10) were assigned to items of damage associated with malignancy, tissue ischaemia, the central nervous system and cardiopulmonary manifestations. The mean scores ranged from 1.3 to 9.5. The highest S.D.s (>=2.5) were associated with forms of damage that may benefit from surgical intervention or may not be causally associated with WG or MPA. Lower scores were assigned by nephrologists in comparison with rheumatologists and by Americans in comparison to Europeans, although the difference in median ranks used by these groups was not statistically significant (P > 0.05 for the comparisons).

Conclusions. This exercise represents an important step in the development of a weighting system that may increase the utility of damage index scores for the assessment of patients with vasculitis.

KEY WORDS: Damage, Morbidity, Disease assessment, Vasculitis, Wegener's granulomatosis, Microscopic polyangiitis, OMERACT

Submitted 8 September 2008; revised version accepted 30 March 2009.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
The Journal of RheumatologyHome page
P. A. MERKEL, K. HERLYN, A. D. MAHR, T. NEOGI, P. SEO, M. WALSH, M. BOERS, and R. LUQMANI
Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9
J Rheumatol, October 1, 2009; 36(10): 2362 - 2368.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.